Three percent of 10,403 adults with COVID-19 pneumonia were diagnosed as having new-onset dementia after a median of 182 days, a significantly higher proportion than that observed with other types of pneumonia, finds a study yesterday in Open Forum Infectious Diseases.
In a phase 3 trial, an investigational oral microbiome therapy was superior to placebo in reducing the risk of recurrent Clostridioides difficile infection, researchers reported yesterday in the New England Journal of Medicine.
A new report shows that global funding for tuberculosis (TB) research is at less than half the goal set by United Nations (UN) member states, with countries falling far short of funding commitments.
Preliminary data from a phase 3 trial in three countries was released this week at an international conference.
About 1.5 million people died from tuberculosis in 2020, up from 1.4 million in 2019, and reporting of cases has dropped substantially.
A clinical trial in the Netherlands found that an antimicrobial stewardship intervention safely reduced broad-spectrum antibiotic use in patients hospitalized with moderately severe pneumonia, Dutch researchers reported yesterday in The Lancet Infectious Diseases.
The data show that 1.2 million fewer people have been diagnosed and treated for TB in 2021 than in 2019.
New data presented today indicate that a shorter treatment regimen for highly drug-resistant forms of tuberculosis (TB) remains highly effective with reduced doses of one of its components.
A Wellcome report yesterday says more research is needed on drug-resistant bacterial infections (DRIs), but current data indicate that DRIs can be more likely to occur—and have more serious ramifications—in people with health conditions like cancer or who have received extensive treatment such as surgery.
The London School of Hygiene and Tropical Medicine (LSHTM) announced today that it is partnering with Johnson & Johnson (J&J) to launch a center focused on research into antimicrobial resistance and tuberculosis (TB).